Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$28.02 USD
+0.01 (0.04%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $28.03 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Myriad Genetics (MYGN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$25.83 | $35.00 | $17.00 | -7.78% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Myriad Genetics comes to $25.83. The forecasts range from a low of $17.00 to a high of $35.00. The average price target represents a decline of 7.78% from the last closing price of $28.01.
Analyst Price Targets (12)
Broker Rating
Myriad Genetics currently has an average brokerage recommendation (ABR) of 2.42 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 2.42 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 41.67% and 8.33% of all recommendations. A month ago, Strong Buy made up 41.67%, while Buy represented 8.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 4 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 4 | 5 |
Sell | 2 | 2 | 2 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.42 | 2.42 | 2.42 | 2.45 | 2.64 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/27/2024 | Scotiabank | Sung-Ji Nam | Not Available | Strong Buy |
6/3/2024 | Not Identified | Not Identified | Not Available | Moderate Sell |
5/8/2024 | Piper Sandler | David M Westenberg | Hold | Hold |
5/8/2024 | SVB Securities | Puneet Souda | Hold | Strong Buy |
5/1/2024 | Stephens | Mason Carrico | Hold | Hold |
4/1/2024 | Cowen & Co. | Daniel Brennan | Hold | Hold |
1/30/2024 | Goldman Sachs | Matthew Sykes | Strong Buy | Strong Buy |
12/14/2023 | Guggenheim Securities | Subbu Nambi | Not Available | Strong Buy |
12/13/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
11/8/2023 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.42 |
ABR (Last week) | 2.42 |
# of Recs in ABR | 12 |
Average Target Price | $25.83 |
LT Growth Rate | 47.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 85 of 252 |
Current Quarter EPS Est: | -0.01 |